Investor Presentation Full Year 2021
117
Investor presentation Full year 2021
Novo Nordisk volume market shares in the three insulin
segments
NAO
USA long-acting insulin
USA premix insulin
USA fast-acting insulin
tMU
tMU
tMU
100
80%
80
80%
80
100%
CAGR volume1: 0.8%
MI penetration²: 66.0%
CAGR volume1: (7.0%)
MI penetration: 47.9%
CAGR volume1: 1.9%
MI penetration: 83.5%
80
80%
60%
60
60
60%
60
60
60
40
40
20
20
0
40%
40
40
20%
20
40% 40
20%
20
0%
0
Nov
Nov
2021
2016
0%
0
Nov
Nov
Nov
2016
2021
2016
Ⓡ
Segment volume
Tresiba
-Levemir
Segment volume
Combined
NovoLog Mix share 70/30
1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units
Source: IQVIA monthly MAT, Nov 2021 volume figures
NN: Novo Nordisk
Segment volume
Ⓡ
Fiasp
60%
40%
20%
0%
Nov
2021
Ⓡ
-NovoRapid
NN combinedView entire presentation